Skip to main content

Table 3 A summary of the scores obtained by frequency of migraine attacks

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

  Univariable Multivariable
Mean ± SD
Median (IQR)
P-value Coefficient (95% CI) P-value
Group
 Active 1.61 ± 0.75
1 (1)
0.0001 0.82 (0.49, 1.14) 0.0001
 Placebo 3.61 ± 0.96
3 (1)
Reference
Sex
 Female 2.44 ± 1.20
3 (2)
0.346 Reference 0.706
 Male 2.86 ± 1.53
3 (3)
0.07 (−0.29, 0.43)
Marital Status
 Single 2.75 ± 1.48
3 (3)
0.502 0.02 (−0.42, 0.45) 0.931
 Married 2.48 ± 1.22
2.5 (2)
Reference
Duration of Migraine
 ≤2 years 2.64 ± 1.40
2.50 (3)
0.765 0.03 (−0.33, 0.39) 0.869
 > 2 years 2.50 ± 1.23
3 (2)
Reference
Age (rho) - 0.06 0.657 0.003 (−0.02, 0.03) 0.817
BMI (rho) 0.02 0.861 0.004 (−0.07, 0.08) 0.911
Number of attack pre-treatment (rho) 0.39 0.002 0.21 (0.06, 0.37) 0.007
  1. BMI Body–mass index, SD Standard deviation, IQR Interquartile range, rho Spearman correlation coefficient